MA33107B1 - 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS - Google Patents

6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS

Info

Publication number
MA33107B1
MA33107B1 MA34152A MA34152A MA33107B1 MA 33107 B1 MA33107 B1 MA 33107B1 MA 34152 A MA34152 A MA 34152A MA 34152 A MA34152 A MA 34152A MA 33107 B1 MA33107 B1 MA 33107B1
Authority
MA
Morocco
Prior art keywords
substituted
triazolopyridazine
benzothiazoles
sulfanyl
medicaments
Prior art date
Application number
MA34152A
Other languages
French (fr)
Inventor
Dominique Damour
Conception Nemececk
Antonio Ugolini
Sylvie Wentzler
Eric Bacque
Original Assignee
Sanofi Sa
Abu Ghazaleh Intellectual Prop
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Abu Ghazaleh Intellectual Prop filed Critical Sanofi Sa
Publication of MA33107B1 publication Critical patent/MA33107B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'INVENTION CONCERNE LES NOUVEAUX PRODUITS DE FORMULE (I): (I) DANS LAQUELLE (II) REPRÉSENTE UNE LIAISON SIMPLE OU DOUBLE; RA REPRÉSENTE -O-Z-RC AVEC Z SIMPLE LIAISON OU ALKYLÈNE ÉVENTUELLEMENT SUBSTITUÉ ET RC REPRÉSENTE CYCLOALKYLE, HÉTÉROCYCLOALKYLE, ARYLE OU HÉTÉROARYLE ÉVENTUELLEMENT SUBSTITUÉS; RB REPRÉSENTE H OU F; AVEC SI RB EST H, ALORS RC N'EST PAS CYCLOALKYLE QUAND Z EST SIMPLE LIAISON ET RC N'EST PAS HÉTÉROCYCLOALKYLE QUAND Z EST ALKYLÈNE; X REPRÉSENTE S, SO OU SO2, A REPRÉSENTE NH OU S; W REPRÉSENTE H, ALKYLE, CYCLOALKYLE OU COR AVEC R REPRÉSENTE CYCLOALKYLE; ALKYLE; ALCOXY; O- PHÉNYLE; -O-(CH2)N-PHÉNYLE AVEC N= 1 À 4; OU NR1 R2 AVEC R1 REPRÉSENTE H OU ALK ET R2 REPRÉSENTE H, CYCLOALKYLE OU ALKYLE; OU BIEN R1, R2 FORMENT AVEC N UN CYCLE RENFERMANT ÉVENTUELLEMENT O, S, N ET/OU NH; TOUS CES RADICAUX ÉTANT ÉVENTUELLEMENT SUBSTITUÉS; CES PRODUITS ÉTANT SOUS TOUTES LES FORMES ISOMÈRES ET LES SELS, À TITRE DE MÉDICAMENTS NOTAMMENT COMME INHIBITEURS DE MET.The invention relates to the novel products of formula (I): (I) in which (II) represents a simple or double bond; RA REPRESENTS -O-Z-RC WITH Z SIMPLE BINDING OR ALKYLENE POSSIBLY SUBSTITUTED AND RC REPRESENTS CYCLOALKYL, HETEROCYCLOALKYL, ARYL OR HETEROARYL THAT ARE POSSIBLY SUBSTITUTED; RB REPRESENTS H OR F; WITH IF RB IS H, THEN RC IS NOT CYCLOALKYLE WHEN Z IS SIMPLE BINDING AND RC IS NOT HETEROCYCLOALKYL WHEN Z IS ALKYLENE; X REPRESENTS S, SO OR SO2, REPRESENTS NH OR S; W REPRESENTS H, ALKYL, CYCLOALKYL OR COR WITH R REPRESENT CYCLOALKYL; Alkyl; ALCOXY; O-PHENYL; -O- (CH 2) N-phenyl with N = 1 to 4; OR NR1 R2 WITH R1 REPRESENTS H OR ALK AND R2 REPRESENTS H, CYCLOALKYL OR ALKYL; OR R1, R2 FORMULA WITH N A CYCLE INCLUDING O, S, N AND / OR NH; ALL THESE RADICALS ARE POSSIBLY SUBSTITUTED; THESE PRODUCTS ARE IN ALL ISOMERIC FORMS AND SALTS, AS MEDICINES IN PARTICULAR AS MET INHIBITORS.

MA34152A 2009-02-06 2010-02-04 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS MA33107B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0900512A FR2941950B1 (en) 2009-02-06 2009-02-06 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS INHIBITORS OF MET.
PCT/FR2010/050178 WO2010089507A1 (en) 2009-02-06 2010-02-04 Derivatives of 6-(6-o-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors

Publications (1)

Publication Number Publication Date
MA33107B1 true MA33107B1 (en) 2012-03-01

Family

ID=40872767

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34152A MA33107B1 (en) 2009-02-06 2010-02-04 6- (6-O-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES DERIVATIVES: PREPARATION, APPLICATION AS MEDICAMENTS AND USE AS MET INHIBITORS

Country Status (19)

Country Link
EP (1) EP2393791A1 (en)
JP (1) JP2012517408A (en)
KR (1) KR20110132560A (en)
CN (1) CN102378759A (en)
AR (1) AR075249A1 (en)
AU (1) AU2010212232A1 (en)
BR (1) BRPI1008232A2 (en)
CA (1) CA2750875A1 (en)
CL (1) CL2011001879A1 (en)
CO (1) CO6400223A2 (en)
EA (1) EA201171011A1 (en)
FR (1) FR2941950B1 (en)
IL (1) IL214406A0 (en)
MA (1) MA33107B1 (en)
MX (1) MX2011008319A (en)
SG (1) SG173559A1 (en)
TW (1) TW201031670A (en)
UY (1) UY32420A (en)
WO (1) WO2010089507A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2691650T3 (en) 2011-09-15 2018-11-28 Novartis Ag 3- (quinolin-6-yl-thio) - [1,2,4] -triazolo- [4,3-a] -pyridines 6-substituted as inhibitors of tyrosine kinase c-Met
CN104024259B (en) 2011-09-27 2017-09-26 基恩菲特公司 It is used as the triazolopyridazine derivates of 6 substitutions of Rev Erb activators
GB201321745D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1298125A1 (en) 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
AU2006320580B2 (en) * 2005-11-30 2011-06-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-Met and uses thereof
BRPI0620292B1 (en) * 2005-12-21 2021-08-24 Janssen Pharmaceutica N. V. TRIAZOLOPYRIDAZINE COMPOUNDS AS KINASE MODULATORS, COMPOSITION, USE, COMBINATION AND PREPARATION PROCESS OF SUCH COMPOUND
EP2032578A2 (en) * 2006-05-30 2009-03-11 Pfizer Products Incorporated Triazolopyridazine derivatives
PE20121506A1 (en) * 2006-07-14 2012-11-26 Amgen Inc TRIAZOLOPYRIDINE COMPOUNDS AS C-MET INHIBITORS
PL2084162T3 (en) * 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Bicyclic triazoles as protein kinase modulators
PA8792501A1 (en) * 2007-08-09 2009-04-23 Sanofi Aventis NEW DERIVATIVES OF 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL AND BENCIMIDAZOL, ITS PREPARATION PROCEDURE, ITS APPLICATION AS MEDICATIONS, PHARMACEUTICAL COMPOSITIONS AND NEW MAIN USE AS MET INHIBITORS.

Also Published As

Publication number Publication date
FR2941950A1 (en) 2010-08-13
EA201171011A1 (en) 2012-03-30
FR2941950B1 (en) 2011-04-01
TW201031670A (en) 2010-09-01
KR20110132560A (en) 2011-12-08
WO2010089507A1 (en) 2010-08-12
MX2011008319A (en) 2012-01-25
AU2010212232A1 (en) 2011-08-25
SG173559A1 (en) 2011-09-29
CL2011001879A1 (en) 2012-01-06
IL214406A0 (en) 2011-09-27
CN102378759A (en) 2012-03-14
UY32420A (en) 2010-09-30
JP2012517408A (en) 2012-08-02
BRPI1008232A2 (en) 2016-03-08
CO6400223A2 (en) 2012-03-15
AR075249A1 (en) 2011-03-16
CA2750875A1 (en) 2010-08-12
EP2393791A1 (en) 2011-12-14

Similar Documents

Publication Publication Date Title
MA31685B1 (en) NOVEL 6-TRIAZOLOPYRIDAZINE-SULFANYL BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE, IN PARTICULAR AS MET INHIBITORS
BRPI0810524B8 (en) (aza)indole derivative, xanthine oxidase inhibitor and pharmaceutical composition comprising said derivative
UY29007A1 (en) DERIVATIVES OF 2-CARBAMIDA-4-FENILTIAZOL, ITS PREPARATION, AND ITS APPLICATION IN THERAPCUTICS
MA29649B1 (en) NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS INHIBITORS OF IKK
GT200600134A (en) NEW COMPOUNDS OF AMINOSULPHONYL DERIVATIVES
BR0306150A (en) Compound, use of a compound, and pharmaceutical composition
MX2009010491A (en) 5-membered heterocyclic derivative and use thereof for medical purposes.
BRPI1007456A2 (en) azaespiranyl alkylcarbamate derivatives of 5-membered heterocyclic compounds, their preparation and their therapeutic application
MX2010001170A (en) Imidazolone derivatives, preparation method thereof and biological use of same.
BRPI0512677A2 (en) quinazoline derivatives
ATE556058T1 (en) 1-(2H)-ISOCHINOLOONE DERIVATIVE
BR112013010552A2 (en) pyridine derivative and medicinal agent
BRPI0510940A (en) 1-aza-bicyclo-3.1.1-nonanes
BRPI0714885B8 (en) therapeutic compounds and their use
MX2009006598A (en) Sulfonamide derivatives as liver carnitine palmitoyl transferase (l-cptl ).
MA33384B1 (en) Heterocyclic sulfonamides, their uses and the pharmaceutical compositions they contain
EA201101334A1 (en) NEW COMPOUNDS BENZOTIADIAZEPINA, METHOD OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING
ATE434603T1 (en) CHINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS
EA200702375A1 (en) UREA DERIVATIVES, METHODS FOR THEIR RECEPTION AND APPLICATION
NO20063865L (en) Heterocyclic substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments
MA30877B1 (en) NOVEL IMIDAZOLON DERIVATIVES, THEIR PREPARATION AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS, USE AS PROTEIN INHIBITORS KINASES IN PARTICULAR CDC7
EA200901474A1 (en) SALTS [4- (6-FLUOR-7-METYLAMINO-2,4-DIOXO-1,4-DIHYDRO-PLAIN-2-CHINAZOLIN-3-IL) -5-CHLORTHIOPHEN-2-ILSULPHONYLMOCHEVANIUM IN VARIOUS CRYSTAL-HEADPHONE-2-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVAN IN VARIOUS CRYSTAL-4-ILSULPHONYLMOCHEVANIUM ON THEIR BASIS
BR0311222A (en) R-enantiomers of pyranoindole derivatives against hepatitis c, their method of obtaining and pharmaceutical composition comprising them
BRPI0813809A2 (en) derivatives of 7-alkynyl -1,8-naphthyridones, their preparation and their application in therapy.
MA33103B1 (en) Derivatives 6 - (substitute 6 - triazolopridzine - sulfanil 5) (A-fluoro-benzotiazole and 5-fluoro-benzimidazole: preparation and use as drugs and as inhibitors)